Media Coverage

Argenta ramps up US research capabilities with two appointments


Jul 06, 2018 - Animal Pharm

By Joseph Harvey
Animal Pharm
July 6, 2018


The New Zealand-headquartered company, which is a contract research and manufacturing specialist, has added Benjamin Isaacs and Amy Wilson.

Dr Isaacs has become the firm's head of pharmaceutical sciences for the US market, while Ms Wilson is now Argenta's director of product development sciences.

Dr Isaacs brings the company extensive experience in the development and manufacturing of biopharma products, as well as knowledge of device formulation, dosage form development and quality aseptic manufacturing experience.

His has a background developing both biologicals and active pharmaceutical ingredients for various regulatory evaluations and attendant filings. Dr Isaacs also has insight into corporate program management, product development and business process improvement.

His most recent role was principal at Acorn2Oak Business Consulting in Gainesville, Florida. He was also principal investigator at Ology Bioservices in Alachua, Florida. Dr Isaacs was the president and chief executive of Formatech in Andover, Massachusetts, for almost 13 years.

Boehringer experience

Ms Wilson provides Argenta with animal health product development know-how. She spent around 20 years at Boehringer Ingelheim Vetmedica in St Joseph, Missouri.

Her experience lies in chemistry, manufacturing and control process development, as well as assay development, validation of formulation processes for multiple formulations, assay test methods and project planning.

Prior to joining Argenta, Ms Wilson was business development manager at Boehringer. She held positions of increased responsibility in the firm's regulatory affairs and research development divisions.

Argenta stated: "With these two key appointments at the Kansas laboratory, Argenta will be ramping up the services provided to customers at this location and the technical support provided to AML Riverside – Argenta's manufacturing facility in Fort Dodge, Iowa. Dr Isaacs and Ms Wilson will also work closely with the members of the Argenta Pharmaceutical Sciences team in Auckland, New Zealand."

At the beginning of last year, Argenta began manufacturing operations in the US. The company purchased the AML Riverside facility in 2016 from Boehringer.

While this is the first Argenta manufacturing site in the US, the company already had two other businesses located stateside. In 2008, Argenta gained a presence in the US when it bought New Jersey-based clinical contract research provider AlcheraBio. It then opened the drug product research laboratory in Kansas during 2011.

Reprinted with permission of Animal Pharm News

Share

Search

Archive

News Releases

Inside the Corridor

KC Animal Health Blog

Investment Forum